FDG-PET in the evaluation of response to nivolumab in recurrent non-small-cell lung cancer

BACKGROUND: Nivolumab, an immune checkpoint inhibitor, is recently clinically applied to non-small cell lung cancer (NSCLC) treatment, and this causes T cell activation and T cell infiltration to tumor tissue through the blockade of the interaction between programmed cell death 1 (PD-1) and programm...

Descripción completa

Detalles Bibliográficos
Autores principales: Higuchi, Mitsunori, Owada, Yuki, Inoue, Takuya, Watanabe, Yuzuru, Yamaura, Takumi, Fukuhara, Mitsuro, Hasegawa, Takeo, Suzuki, Hiroyuki
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2016
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5011843/
https://www.ncbi.nlm.nih.gov/pubmed/27595749
http://dx.doi.org/10.1186/s12957-016-0998-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5011843/
https://www.ncbi.nlm.nih.gov/pubmed/27595749
http://dx.doi.org/10.1186/s12957-016-0998-y

Ejemplares similares